2022 AGM – Meeting Recording

November 11, 2022May 23, 2023 Alterity Therapeutics

2022

Post navigation

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy
Alterity Therapeutics Raises A$40.0 million in Placement
Alterity Therapeutics Announces Funding to Accelerate ATH434 Clinical and Business Development Activities
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

2022 AGM – Meeting Recording

Related Posts

Prana completes PBT2 dosing in IMAGINE Alzheimer’s Disease clinical trial

Prana Enrolls First Patient in the “Reach2HD” Phase II Huntington Disease Trial

Prana Appoints David Stamler as Chief Medical Officer to Lead Clinical Development